ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pliva suitors up the ante

September 18, 2006 | APPEARED IN VOLUME 84, ISSUE 38

Barr Pharmaceuticals and Iceland's Actavis Group continue to battle for control of Croatian drug firm Pliva. In the latest development, Barr has matched the $2.5 billion offer made by Actavis in August. The saga began in March, when Actavis made Pliva an unsolicited $1.6 billion bid, which was later sweetened to $1.9 billion. Barr came into the picture in June, when it made a $2.2 billion offer for the firm. Though Pliva appears to be favoring Barr, Actavis has not given up, causing the price tag to creep up over the past six months.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment